Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
01 April 2021 | Story Andre Damons | Photo istock
The Easter weekend runs the risk of being a major catalyst for the third wave and people’s behaviour will be the primary driver of transmission for the third wave.

Similar trends as during the festive season of 2020 – when the behaviour of people was driving COVID-19 transmissions and played a role in the second wave – have emerged due to the Easter holidays, and may contribute to a third wave. 
“This means that we can already anticipate gatherings and a higher rate of travel during the next three weeks. As a result of this as well as non-adherence to the non-pharmaceutical interventions, we can anticipate this event to serve as a catalyst for transmission.” 

“If nothing is done to prevent this, it is anticipated that the Free State will see a steady increase and a potential third wave between 17 April and 26 June,” says Herkulaas Combrink, the interim Director of the UFS Initiatives for Digital Futures and PhD candidate in Computer Science at the University of Pretoria (UP).

The Easter weekend runs the risk of being a major catalyst for the third wave

According to him, the vulnerability and population density dynamics in each province, the behaviour of people, and the social norms between communities must be taken into consideration to contextualise the impact of Easter on disease transmission – especially when looking at SARS-CoV-2.

For the Free State, the Easter weekend runs the risk of being a major catalyst that will lead up to the third wave, says Combrink. “If no interventions are put in place and people do not adhere to non-pharmaceutical interventions to mitigate the spread of the disease, then we will see a steady climb and increase in cases up until that time. This means that the behaviour of people will be the primary driver of transmission for the third wave.”

Reducing the severity of the third wave

According to Combrink, who is involved in risk communication and vaccine analytics with other members of the UFS, we may be able to reduce the severity of the third wave if the variant remains the same and the vaccination roll-out plan is in full effect. It will also help if the correct number of people are vaccinated, the general population adheres to PPE and mitigation strategies, and people practise the appropriate behaviour as indicated in all official COVID-19 communication, including the UFS COVID-19 information page.  

According to Prof Felicity Burt and Dr Sabeehah Vawda, both virology experts in the UFS Division of Virology, the current vaccination programme is aimed at reducing the severity of the disease among health-care workers. Prevention of further waves of infection through vaccination will require sufficient coverage to induce at least 70% herd immunity in the country. Currently, no country has achieved that level of herd immunity through vaccine programmes – this is the long-term goal of vaccination. 

“Irrespective of the government’s vaccination programmes and schedules and a virus that may mutate and perhaps become more virulent, the fundamental ways to protect yourself remain unchanged, namely social distancing, wearing of masks, and regular hand washing. People need to realise that this ‘new normal’ is going to be with us for a while and remains the best defence against all SARS-CoV-2 viruses and even provides protection against other respiratory pathogens.”

Vaccines and mutations

The exact frequency of mutations differs between different types of viruses, but generally, SARS-CoV-2 is known to have a slower ‘mutation rate’ than other RNA viruses because of its built-in ‘proofreading’ enzyme. The true mutation rate of a virus is difficult to measure, as the majority of mutations will be lethal to the virus. Irrespective, very few have actually resulted in clinical impact. 

“This highlights the rather gradual process of mutation, so vaccines should remain effective or at least partially effective in the near future, as they elicit antibodies that target different parts of the virus. Continuous surveillance of SARS-CoV-2 is necessary and ongoing to monitor for changes that may impact vaccines and diagnostic tests,” the experts say.

According to Prof Burt and Dr Vawda, scientists are continuously monitoring the situation to detect if the current vaccines would remain effective and to try to adjust them accordingly. How or when the virus will mutate in a clinically significant way is unknown, so at this point, the current vaccines have been shown to be effective against severe disease and hence have application in reducing significant disease. 

“There remains a lot unknown about the extent of protection and the duration of protection, and it is obviously hoped that the vaccine’s immune response in the human body would be able to provide at least some protection or decrease the possibility of severe disease even against potentially newer variants.”

News Archive

Inaugural lecture: Prof Robert Bragg, Dept. of Microbial, Biochemical and Food Biotechnology
2006-05-17



Attending the inaugural lecture were in front from the left Prof Robert Bragg (lecturer at the Department of Microbial, Biochemical and Food Biotechnology) and Frederick Fourie (Rector and Vice-Chancellor).  At the back from the left were Prof James du Preez (Departmental Chairperson:  Department of Microbial, Biochemical and Food Biotechnology) and Prof Herman van Schalkwyk (Dean: Faculty of Natural and Agricultural Sciences). Photo: Stephen Collett
 

A summary of an inaugural lecture delivered by Prof Robert Bragg at the University of the Free State:

CONTROL OF INFECTIOUS AVIAN DISEASES – LESSONS FOR MAN?

Prof Robert R Bragg
Department of Microbial, Biochemical and Food Biotechnology
University of the Free State

“Many of the lessons learnt in disease control in poultry will have application on human medicine,” said Prof Robert Bragg, lecturer at the University of the Free State’s (UFS) Department of Microbial, Biochemical and Food Biotechnology during his inaugural lecture.

Prof Bragg said the development of vaccines remains the main stay of disease control in humans as well as in avian species.  Disease control can not rely on vaccination alone and other disease-control options must be examined.  

“With the increasing problems of antibiotic resistance, the use of disinfection and bio security are becoming more important,” he said.

“Avian influenza (AI) is an example of a disease which can spread from birds to humans.  Hopefully this virus will not develop human to human transmission,” said Prof Bragg.

According to Prof Bragg, South Africa is not on the migration route of water birds, which are the main transmitters of AI.  “This makes South Africa one of the countries less likely to get the disease,” he said.

If the AI virus does develop human to human transmission, it could make the 1918 flu pandemic pale into insignificance.  During the 1918 flu pandemic, the virus had a mortality rate of only 3%, yet more than 50 million people died.

Although the AI virus has not developed human-to-human transmission, all human cases have been related to direct contact with infected birds. The mortality rate in humans who have contracted this virus is 67%.

“Apart from the obvious fears for the human population, this virus is a very serious poultry pathogen and can cause 100% mortality in poultry populations.  Poultry meat and egg production is the staple protein source in most countries around the world. The virus is currently devastating the poultry industry world-wide,” said Prof Bragg.

Prof Bragg’s research activities on avian diseases started off with the investigation of diseases in poultry.  “The average life cycle of a broiler chicken is 42 days.  After this short time, they are slaughtered.  As a result of the short generation time in poultry, one can observe changes in microbial populations as a result of the use of vaccines, antibiotics and disinfectants,” said Prof Bragg.   

“Much of my research effort has been directed towards the control of infectious coryza in layers, which is caused by the bacterium Avibacterium paragallinarum.  This disease is a type of sinusitis in the layer chickens and can cause a drop in egg product of up to 40%,” said Prof Bragg.

The vaccines used around the world in an attempt to control this disease are all inactivated vaccines. One of the most important points is the selection of the correct strains of the bacterium to use in the vaccine.

Prof Bragg established that in South Africa, there are four different serovars of the bacterium and one of these, the serovar C-3 strain, was believed to be unique to Southern Africa. He also recently discovered this serovar for the first time in Israel, thus indicating that this serovar might have a wider distribution than originally believed.

Vaccines used in this country did not contain this serovar.  Prof Bragg established that the long term use of vaccines not containing the local South African strain resulted in a shift in the population distribution of the pathogen.

Prof Bragg’s research activities also include disease control in parrots and pigeons.   “One of the main research projects in my group is on the disease in parrots caused by the circovirus Beak and Feather Disease virus. This virus causes serious problems in the parrot breeding industry in this country. This virus is also threatening the highly endangered and endemic Cape Parrot,” said Prof Bragg.

Prof Bragg’s research group is currently working on the development of a DNA vaccine which will assist in the control of the disease, not only in the parrot breeding industry, but also to help the highly endangered Cape Parrot in its battle for survival.

“Not all of our research efforts are directed towards infectious coryza or the Beak and Feather Disease virus.  One of my Masters students is currently investigating the cell receptors involved in the binding of Newcastle Disease virus to cancerous cells and normal cells of humans. This work will also eventually lead to a possible treatment of cancer in humans and will assist with the development of a recombinant vaccine for Newcastle disease virus,” said Prof Bragg.

We are also currently investigating an “unknown” virus which causes disease problems in poultry in the Western Cape,” said Prof Bragg.
 
“Although disinfection has been extensively used in the poultry industry, it has only been done at the pre-placement stage. In other words, disinfectants are used before the birds are placed into the house. Once the birds are placed, all use of disinfectants stops,” said Prof Bragg.

“Disinfection and bio security can be seen as the ‘Cinderella’ of disease control in poultry.  This is also true for human medicine. One just has to look at the high numbers of people who die from hospital-acquired infections to realise that disinfection is not a concept which is really clear in human health care,” said Prof Bragg.

Much research has been done in the control of diseases through vaccination and through the use of antibiotics. “These pillars of disease control are, however, starting to crumble and more effort is needed on disinfection and bio security,” said Prof Bragg.

Prof Bragg has been working in close co-operation with a chemical manufacturing company in Stellenbosch to develop a unique disinfectant which his highly effective yet not toxic to the birds.

As a result of this unique product, he has developed the continual disinfection program for use in poultry. In this program the disinfectant is used throughout the production cycle of the birds. It is also used to ensure that there is excellent pre-placement disinfection.

“The program is extensively used for the control of infectious diseases in the parrot-breeding industry in South Africa and the product has been registered in 15 countries around the world with registration in the USA in the final process,” said Prof Bragg.

“Although the problem of plasmid mediated resistance to disinfectants is starting to rear its ugly head, this has allowed for the opening of a new research field which my group will hopefully exploit in the near future,” he said.

 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept